美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Accustem Sciences Inc.

0.1600

0.0000

成交量：78

成交額：14.20

市值：257.16萬

市盈率：-1.52

高：0.1600

開：0.1600

低：0.1600

收：0.1600

52周最高：2.25

52周最低：0.1515

股本：1,607.23萬

流通股本：788.60萬

量比：0.01

換手率：0.00%

股息：- -

股息率：- -

每股收益(TTM):-0.1055

淨資產收益率：-1794.16%

總資產收益率：-64.16%

市淨率：-0.62

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Accustem Sciences Inc.

交易所：

OTCQB

成立時間：

2013

員工人數：

4

公司地址：

5 Penn Plaza,19th Floor,#1954,New York,New York,United States

官網：

- -

郵編：

10001

電話：

- -

傳真：

- -

簡介：

AccuStem Sciences, Inc.於2021年7月28日在美國特拉華州成立。該公司是一家臨床階段診斷公司，致力於改善全球每年1800多萬癌症患者的生活質量和預后。該公司的計劃是開發一套新的基因組測試並將其商業化，以支持整個腫瘤治療過程中的決策。該公司的重點將是將該公司的專有基因組測試StemPrintER用於早期乳腺癌患者的商業化。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/ACUT/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ACUT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACUT\",,,,,undefined,":{"symbol":"ACUT","market":"US","secType":"STK","nameCN":"Accustem Sciences Inc.","latestPrice":0.16,"timestamp":1787592614830,"preClose":0.16,"halted":0,"volume":78,"delay":15,"changeRate":0,"floatShares":7885954,"shares":16072267,"eps":-0.105519,"marketStatus":"交易中","change":0,"latestTime":"08-24 13:30:14 EDT 延時","open":0.16,"high":0.16,"low":0.16,"amount":14.201,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.105519,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"exchange":"OTCQB","adjPreClose":0.16,"volumeRatio":0.009556},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ACUT\",,,,,undefined,":{"symbol":"ACUT","floatShares":7885954,"roa":"-64.16%","roe":"-1794.16%","lyrEps":0,"volumeRatio":0.009556,"shares":16072267,"dividePrice":0,"high":0.16,"amplitude":0,"preClose":0.16,"low":0.16,"week52Low":0.1515,"pbRate":"-0.62","psRate":"26.13","week52High":2.25,"institutionHeld":0,"latestPrice":0.16,"eps":-0.105519,"divideRate":0,"volume":78,"delay":15,"ttmEps":-0.105519,"open":0.16,"prevYearClose":0.81351,"prevWeekClose":0.16,"prevMonthClose":0.2095,"prevQuarterClose":0.2854,"fiveDayClose":0.2391,"twentyDayClose":0.19,"sixtyDayClose":0.2575},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ACUT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-09-16","symbol":"ACUT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1726459200000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-05-20","symbol":"ACUT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1716177600000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ACUT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ACUT\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":669855648,"yearFounded":2013,"employeeNum":4,"address":"5 Penn Plaza,19th Floor,#1954,New York,New York,United States","zipCode":"10001","fiscalYearEnd":"12-31"},"stockCompanyDetail":{"description":"AccuStem Sciences, Inc.於2021年7月28日在美國特拉華州成立。該公司是一家臨床階段診斷公司，致力於改善全球每年1800多萬癌症患者的生活質量和預后。該公司的計劃是開發一套新的基因組測試並將其商業化，以支持整個腫瘤治療過程中的決策。該公司的重點將是將該公司的專有基因組測試StemPrintER用於早期乳腺癌患者的商業化。","exchange":"OTCQB","name":"Accustem Sciences Inc.","nameEN":"Accustem Sciences Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"ACUT\",market:\"US\",,,undefined,":null}}